A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

This study is testing a four-drug combination — chidamide (an epigenetic drug), a PD-L1 immunotherapy blocker, carboplatin (chemotherapy), and etoposide (chemotherapy) — as a first-line treatment for people with extensive-stage small-cell lung cancer (a fast-growing type of lung cancer that has spread widely). **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with extensive-stage small-cell lung cancer and have not received any prior treatment for it - You are in good physical condition (ECOG 0–1) - You have at least one measurable tumor lesion - Your organ function (blood counts, liver, kidneys, heart) meets required levels - You are willing to use effective contraception during and after treatment **You may NOT be eligible if...** - You have previously received an HDAC inhibitor or immunotherapy - You have another active cancer within the past 5 years (certain cured cancers may be acceptable) - You have HIV, immunodeficiency, or have had an organ transplant - You have uncontrolled heart disease or a prolonged QTc interval on ECG - You are pregnant or breastfeeding - You have a history of neurological or psychiatric disorders Talk to your doctor to see if this trial is right for you.